Satellos Bioscience Inc. announced results from multiple preclinical studies in a disease model of Duchenne muscular dystrophy ("Duchenne"). Satellos' proprietary MyoReGenXTM assay platform identified a protein kinase (codenamed "K9") as a potential drug target to modulate polarity in muscle stem cells. Using a known inhibitor of this kinase target as a reference compound for generating Proof of Concept to guide future drug development efforts with its own compounds, Satellos treated Mdx mice, a gold-standard experimental model for studying Duchenne, for a period of two (2) weeks.

Drug treated muscles were larger in size than untreated control muscles by an average of 40% and displayed about a 25% increase in ability to generate force, approaching levels seen in normal mice. Satellos believes that a dysfunction in the normal process of stem cell polarity in response to muscle damage represents a previously unrecognized root cause of Duchenne. The goal of correcting polarity in Duchenne is to restore the body's innate ability to regenerate muscle in response to the ongoing damage experienced by people living with Duchenne.

SAT-3153 has been designated by Satellos as its lead drug candidate and the Company is pursuing pre-IND development activities.